Protelos to remain available with further restrictions
Protelos (strontium ranelate) will not be fully withdrawn but further restrictions will be applied to its use, following a final review by the European Medicines Agency. The Agency has recommended further restricting the use of the medicine to patients who cannot be treated with other medicines approved for osteoporosis. In addition these people should continue to be evaluated regularly by their doctor and treatment should be stopped if they develop heart or circulatory problems, such as uncontrolled high blood pressure or angina. As recommended in a previous review, patients who have a history of certain heart or circulatory problems, such as stroke and heart attack, must not use the medicine.